TSC-101 enters Phase 3 ALLOHA-2 in AML/MDS post-HCT; pivotal RFS data will determine whether Phase 1 signals translate to registrational benefit

Bull

A positive outcome would be a statistically significant improvement in relapse-free survival in the TSC-101 arm versus the biologically-assigned internal control, consistent with the Phase 1 hazard ratio signal (HR ~0.50) but powered to reach conventional significance thresholds. Durable two-year RFS rates comparable to the 100% seen in the small Phase 1 cohort, coupled with a clean safety profile and no new graft-versus-host disease signals, would support an NDA/BLA submission and position TSC-101 as a standard-of-care prophylactic cell therapy in AML/MDS post-HCT.

Bear

The most likely failure modes are dilution of the RFS benefit in a larger, more heterogeneous patient population — the Phase 1 control arm was small (n=4 at two years) and the HR of 0.50 was non-significant — or the emergence of clinically meaningful graft-versus-host disease at higher cumulative doses that limits the therapeutic window. Manufacturing failures beyond the ~10% rate observed in Cohort C, or difficulty enrolling a sufficiently balanced control arm given the biologically-assigned design, could also compromise trial integrity and delay or invalidate the primary endpoint.